Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | TSPO | P30536 | 1/20 | 0.42 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.42 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.42 |
| ▸ | STAT5B | P51692 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | JAK2 | O60674 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16989216 | 0.87 | TSPO (0.47) | POLBSMN1; SMN2GAAMEN1KMT2A | |
| SCHEMBL29075996 | 0.85 | POLB (0.69) | POLBSMN1; SMN2GAAMEN1KMT2A | |
| SCHEMBL828561 | 0.83 | NPC1 (0.39) | SMN1; SMN2MEN1KMT2ALMNANPC1 | |
| SCHEMBL15074514 | 0.80 | SSTR4 (0.39) | SMN1; SMN2GAAHDAC1NPC1ALDH1A1 | |
| SCHEMBL828100 | 0.80 | F2 (0.40) | SMN1; SMN2NPC1RAB9A | |
| SCHEMBL22703137 | 0.80 | TSHR (0.39) | SMN1; SMN2TSHRNPC1ALDH1A1RAB9A | |
| SCHEMBL15286418 | 0.80 | CKS1B (0.38) | POLBSMN1; SMN2MEN1KMT2AHDAC3 | |
| SCHEMBL860084 | 0.79 | SMN1; SMN2 (0.36) | SMN1; SMN2MEN1KMT2ALMNANPC1 | |
| SCHEMBL828344 | 0.79 | POLB (0.42) | POLBMEN1KMT2ALMNATSHR | |
| SCHEMBL17282348 | 0.79 | TSHR (0.39) | SMN1; SMN2LMNATSHRNPC1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170313661-A1 | KINASE MODULATORS FOR THE TREATMENT OF CANCER | SYNOVO GMBH (DE) | 2017-11-02 | — | — | US | disclosed |
| US-20170313661-A1 | KINASE MODULATORS FOR THE TREATMENT OF CANCER | SYNOVO GMBH (DE) | 2017-11-02 | — | — | US | disclosed |
| US-20170313661-A1 | KINASE MODULATORS FOR THE TREATMENT OF CANCER | SYNOVO GMBH (DE) | 2017-11-02 | — | — | US | disclosed |
| US-9617221-B2 | Kinase modulators for the treatment of cancer | SYNOVO GMBH (DE) | 2017-04-11 | — | — | US | disclosed |
| US-9617221-B2 | Kinase modulators for the treatment of cancer | SYNOVO GMBH (DE) | 2017-04-11 | — | — | US | disclosed |
| US-20130045938-A1 | KINASE MODULATORS FOR THE TREATMENT OF CANCER | SYNOVO GMBH (DE) | 2013-02-21 | — | — | US | disclosed |
| US-20130045938-A1 | KINASE MODULATORS FOR THE TREATMENT OF CANCER | SYNOVO GMBH (DE) | 2013-02-21 | — | — | US | disclosed |
| US-8143294-B2 | 2-sulfanyl-substituted imidazole derivatives and their use as cytokine inhibitors | BURNET MICHAEL (DE) | 2012-03-27 | — | — | US | disclosed |
| US-8143294-B2 | 2-sulfanyl-substituted imidazole derivatives and their use as cytokine inhibitors | BURNET MICHAEL (DE) | 2012-03-27 | — | — | US | disclosed |
| US-8143294-B2 | 2-sulfanyl-substituted imidazole derivatives and their use as cytokine inhibitors | BURNET MICHAEL (DE) | 2012-03-27 | — | — | US | disclosed |
| WO-2011100769-A2 | KINASE MODULATORS FOR THE TREATMENT OF CANCER | SYNOVO GMBH (DE) | 2011-08-18 | — | — | WO | disclosed |
| US-20090270462-A1 | 2-SULFANYL-SUBSTITUTED IMIDAZOLE DERIVATIVES AND THEIR USE AS CYTOKINE INHIBITORS | SYNOVO GMBH (DE) | 2009-10-29 | — | — | US | disclosed |
| US-20090270462-A1 | 2-SULFANYL-SUBSTITUTED IMIDAZOLE DERIVATIVES AND THEIR USE AS CYTOKINE INHIBITORS | SYNOVO GMBH (DE) | 2009-10-29 | — | — | US | disclosed |
| US-20090270462-A1 | 2-SULFANYL-SUBSTITUTED IMIDAZOLE DERIVATIVES AND THEIR USE AS CYTOKINE INHIBITORS | SYNOVO GMBH (DE) | 2009-10-29 | — | — | US | disclosed |
| EP-1140939-B1 | SUBSTITUTED 2-ARYL-3-(HETEROARYL)-IMIDAZO[1,2-ALPHA]PYRIMIDINES, AND RELATED PHARMACEUTICAL COMPOSITIONS AND METHODS | ORTHO MCNEIL PHARM INC (US) | 2005-02-09 | — | — | EP | disclosed |
| US-6610697-B1 | Treating rheumatoid arthritis | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2003-08-26 | — | — | US | disclosed |
| EP-1140939-A1 | SUBSTITUTED 2-ARYL-3-(HETEROARYL)-IMIDAZO[1,2-ALPHA]PYRIMIDINES, AND RELATED PHARMACEUTICAL COMPOSITIONS AND METHODS | Ortho-Mcneil Pharmaceutical, Inc. (US) | 2001-10-10 | — | — | EP | disclosed |
| WO-2001034605-A1 | SUBSTITUTED 2-ARYL-3-(HETEROARYL)-IMIDAZO[1,2-a]PYRIMIDINES, AND RELATED PHARMACEUTICAL COMPOSITIONS AND METHODS | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2001-05-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170313661-A1 | KINASE MODULATORS FOR THE TREATMENT OF CANCER | MAP3K10, MAP3K12, MAP3K20 | POLB 2411/4885SMN1; SMN2 4665/4885GAA 2734/4885 |
| US-20130045938-A1 | KINASE MODULATORS FOR THE TREATMENT OF CANCER | MAP3K10, MAP3K12, MAP3K20 | POLB 2411/4885SMN1; SMN2 4665/4885GAA 2734/4885 |
| US-20090270462-A1 | 2-SULFANYL-SUBSTITUTED IMIDAZOLE DERIVATIVES AND THEIR USE AS CYTOKINE INHIBITORS | IL2, IL2RA, IL1B | POLB 3752/4885SMN1; SMN2 4574/4885GAA 3338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.